| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8537567 | Progress in Neuro-Psychopharmacology and Biological Psychiatry | 2018 | 18 Pages |
Abstract
Our results suggest that mianserin, a clinically-available anti-depressant, may be effective to alleviate both PD psychosis and dyskinesia, but may hinder l-DOPA anti-parkinsonian action, which limits its potential clinical usefulness.
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Adjia Hamadjida, Stephen G. Nuara, Jim C. Gourdon, Philippe Huot,